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Previous studies demonstrated that peptides produced by the hydrolysis of olive 21 
seed proteins using Alcalase enzyme showed in vitro multifunctional lipid-lowering 22 
capability. This work presents a deeper insight in the hypolipidemic effect of olive seed 23 
peptides. The capability of olive seed peptides to inhibit endogenous cholesterol 24 
biosynthesis through the inhibition of HMG-CoA reductase enzyme was evaluated 25 
observing a 38 ± 7% of inhibition in comparison with a blank. Two in vivo assays using 26 
different peptides concentrations were designed to evaluate the hypolipidemic effect of 27 
olive seed peptides in male and female mice. A low concentration of hydrolysate (200 28 
mg/kg/day) reduced total cholesterol in male mice in a 20% after 11 weeks treatment 29 
compared to the mice feeding the hypercholesterolemic diet. A higher hydrolysate 30 
concentration (400 mg/kg/day) showed a greater reduction in total cholesterol (25%). 31 
Hypocholesterolemic effect was attributed to the capacity of the hydrolysate to increase 32 
HDL cholesterol and to decrease LDL cholesterol. The analysis of the olive seed 33 
hydrolysate by RP-HPLC-MS/MS enabled the identification of peptides that could be 34 
responsible for this hypolipidemic effect. 35 
 36 





1. Introduction 40 
Cardiovascular diseases are a serious worldwide health problem. Indeed, above 41 
31 % of all world deaths are due to these diseases.1 Main risk factor in the development 42 
of cardiovascular diseases is hyperlipidemia, characterized by high serum triglycerides 43 
and cholesterol levels.  44 
There are different strategies to treat hyperlipidemia. Most of these strategies are 45 
based on the disruption of micellar cholesterol transport and the inhibition of enzymes 46 
involved in the absorption and biosynthesis of cholesterol and triglycerides. In fact, 47 
cholesterol is solubilised in micelles for its transportation and absorption and, thus, the 48 
displacement of cholesterol in micelles has been a target to decrease cholesterol 49 
absorption.2 Moreover, the inhibition of the pancreatic cholesterol esterase enzyme, that 50 
hydrolysates dietary cholesterol esters into free cholesterol, also results in the reduction 51 
of the bioavailability of dietary cholesterol esters.3 Additionally, oxidation of endogenous 52 
cholesterol produces bile acids in the liver and the sequestering of bile acids has been an 53 
additional strategy to decrease plasma cholesterol level.4 Regarding triglycerides, their 54 
absorption can be ameliorated by the inhibition of pancreatic lipase enzyme that is 55 
responsible for their hydrolysis into monoglycerides and free fatty acids.5 Furthermore, 56 
biosynthesis of endogenous cholesterol consists of different cascade reactions and a 57 
proposed mechanism to disrupt cholesterol biosynthesis is based on the inhibition of the 58 
3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA, EC 1.1.1.34) reductase enzyme 59 
that catalyses the rate-limiting step in this process.6  60 
Different synthetic drugs based on previous strategies (inhibitors of cholesterol 61 
endogenous synthesis, inhibitors of membrane proteins that promote the intestinal 62 
absorption of cholesterol, bile acid sequestrants, etc.) have been developed for the 63 
treatment of hyperlipidemia. However, these drugs can cause diverse side effects 64 
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including digestive disturbances, nausea, increase of hepatic transaminases and creatine 65 
kinase, muscle weakness, headache, etc.7,8 On the other hand, there is an increasing 66 
interest in searching for alternative natural compounds to treat and/or prevent 67 
hyperlipidemia. Different authors have demonstrated that peptides from soybean, lupin, 68 
rice bran, potato, seafood, and fish9-10 could exert in vitro hypolipidemic activity. An 69 
additional source of lipid-lowering peptides are some food by-products. Moreover, the 70 
exploitation of food by-products contributes to the sustainability of food processing. As 71 
example, our research group demonstrated, in a previous work, that peptides from olive 72 
seeds proteins presented in vitro multifunctional lipid-lowering capacity. Indeed, olive 73 
seed peptides could decrease exogenous lipid absorption by the reduction of the micellar 74 
cholesterol solubility and the inhibition of cholesterol esterase and pancreatic lipase 75 
enzymes.11  76 
Despite in vitro experiments are useful as a preliminary evaluation of potential 77 
bioactivity, physiological processes and components bioavailability can make that in vitro 78 
activity was not correlated with results at in vivo level. The main aim of this work was to 79 
further investigate the hypolipidemic capacity of the olive seed hydrolysate by studying 80 
its capacity to inhibit the biosynthesis of cholesterol, its cytotoxicity, and its effect at 81 
physiological level. Moreover, peptides potentially responsible of this effect were 82 
identified by HPLC-MS/MS.  83 
  84 
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2. Materials and methods 85 
2.1 Chemicals 86 
Water was obtained with a Milli-Q system from Millipore (Bedford, MA, USA). 87 
Acetone, hydrochloric acid (HCl), acetonitrile (ACN), and acetic acid (AA) were 88 
obtained from Scharlau (Barcelona, Spain). Tris(hydroxymethyl)aminomethane (Tris), 89 
sodium dodecyl sulfate (SDS), and di-sodium tetraborate were from Merck (Darmstadt, 90 
Germany). DL-dithiothreitol (DTT), albumin from bovine serum (BSA), β-91 
mercaptoethanol, o-phthaldialdehyde (OPA), L-glutathione (GSH), 3-[4,5-92 
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide 93 
(DMSO), Dulbecco's modified eagle's medium (DMEM), antibiotics (penicillin, 94 
streptomycin, and amphotericin), fetal bovine serum, phosphate buffered (PB), and the 95 
HMGCoA-reductase (HMGR) assay kit were purchased in Sigma-Aldrich (St. Louis, 96 
MO, USA). Bradford reagent (Coomassie Blue G-250) was acquired at Bio-Rad 97 
(Hercules, CA, USA). All the chemicals were analytical grade, except for ACN and AA, 98 
which were MS grade. Ezetimibe was obtained from Merck Sharp & Dohme (Kenilworth, 99 
NJ, USA) and Alcalase 2.4 L FG (EC 3.4.21.62) was kindly donated by Novozymes Spain 100 
S.A. (Madrid, Spain). All cell lines (HeLa and HK-2) were from the American Type 101 
Culture Collection (Rockwell, MD, USA).  102 
 103 
2.2 Production of hydrolysate 104 
Raw olives of ‘Manzanilla’ variety were kindly donated by the olive company 105 
FAROLIVA S.L. (Murcia, Spain). Olive seeds were extracted from olive stones by 106 
manual pressing. Olive seeds were next ground in a domestic mill and defatted with 107 
hexane for 30 min (four times). Defatted seeds were dried at room temperature. Seed 108 
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proteins were extracted and digested following the method described by Prados et al.11 109 
Briefly, 0.03 g of deffated olive seed were mixed with 5 mL of 0.1 M Tris-HCl buffer 110 
containing 0.5% SDS and 0.5% DTT (pH 7.5). For that purpose, a high intensity focus 111 
ultrasonic (HIFU) probe (model VCX130, Sonic Vibra-Cell, Hartford, CT, USA) was 112 
employed at a 30% of amplitude for 5 min. After centrifugation of the extract at 6000g 113 
for 10 min, supernatant containing proteins was collected. Proteins were next precipitated 114 
with cold acetone for 24 h followed by centrifucation and drying. Finally, proteins were 115 
dissolved in a 5 mM borate buffer (pH 8.5) and hydrolyzed with Alcalase at 50 ºC for 4 116 
h. Protein concentration was estimated by Bradford assay12 and content of peptides was 117 
determined using OPA assay.11 118 
 119 
2.3 HMGR in vitro assay 120 
HMGR inhibition assay was carried out following the method used by Marques 121 
et al.13 HMGR assay kit included the assay buffer, pravastatin, β-nicotinamide adenine 122 
dinucleotide 2’-phosphate reduced tetrasodium salt hydrate (NADPH), HMGCoA, and 123 
HMGR enzyme. Solutions containing 181 µL of the assay buffer (diluted 5 times), 1 µL 124 
of inhibitor (pravastatin/sample), 4 µL of NADPH, 12 µL of HMGCoA, and 2 µL of 125 
HMGR enzyme were prepared. After mixing the sample thoroughly, the absorbance of 126 
the NADPH was measured every 10 s up to 10 min at a wavelength of 340 nm. The 127 
activity (A) of HMGR, expressed as µmol of oxidized NADPH/min/mg protein, was 128 
calculated using the following equation: 129 
A =
(Abs /min − Abs /min ) ∙ TV




where TV is the total volume (mL), V is the volume of enzyme (mL), 0.6 is the enzyme 131 
concentration in mg protein/mL, LP is the light path (cm), 12.44 is the product of the 132 
molar absorption coefficient of NADPH at 340 nm (6.22 mM-1 cm-1) by two (number of 133 
NADPH molecules consumed in the reaction), Abs340/minsample is the absorbance 134 
observed when adding the hydrolysate, and Abs340/minblank is the absorbance 135 
corresponding to the blank. Each sample was measured by triplicate. Two different 136 
concentrations of hydrolysate were measured, 3.1 mg/mL and 26.7 mg/mL. The 137 
percentage of inhibition of HMGR was calculated as: 138 
% inhibition of HMGR =
A á − A
A á
× 100 139 
where Amáx is the activity of the enzyme without inhibitor and Asample is the activity of the 140 
enzyme when adding sample or pravastatin.  141 
 142 
2.4 Cytotoxicity of the olive seed hydrolysate 143 
The MTT assay was carried out following the method described by Prados et al.11 144 
Different concentrations of the olive seed hydrolysate were used, and two different cell 145 
lines were employed: a cancer cell line (HeLa, human cervical cancer cells) and a healthy 146 
cell line (HK-2, human renal proximal tubule cells). Cell bioavailability was expressed 147 
related to the control (hydrolysis buffer).  148 
 149 
2.5 Animals 150 
Six-month-old C57BL/6 mice (20-30 g weight) from Envigo (Huntingdom, UK) were 151 
housed at the Animal Research Centre of the University in groups of two or three animal 152 
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per cage with stable room conditions as room temperature (20-24 ºC), 55 ± 10% of 153 
humidity and a 12:12 h dark/light cycle. All animals were fed ad libitum. Two kinds of 154 
diets were used to feed the mice, a standard laboratory animals’ diet (Teklad ref. 2014) 155 
and a high cholesterol diet (HCD) (Teklad ref. TD.88051), both from Envigo. The animals 156 
were supplemented by oral gavage and euthanized at the end of the studies by Oxygen 157 
Dioxide and terminal heart puncture. Blood samples were collected to determine plasma 158 
lipid profile. 159 
The in vivo assays with animals were carried out implementing the European 160 
Directive 63/2010/EU and the Spanish regulations (RD 53/2013) on animal 161 
experimentation. These assays were favourably assessed by the Ethics Committee of the 162 
University of Alcalá (CEI: CEI-UAH-AN-2015006) and authorized by the Spanish 163 
Competent Authority (PROEX 223/18). 164 
 165 
2.6 In vivo experiment design 166 
Two sets of in vivo assays were designed using two different doses of the olive 167 
seed hydrolysate. In all cases, the animals were supplemented once per day, at 10:00 in 168 
the morning. In the first study, male and female mice were divided in the following four 169 
groups. Group 1 was fed with a standard diet and supplemented with a low concentration 170 
of hydrolysate (200 mg/kg/day) while group 2 was supplemented with the same dose but 171 
fed with HCD. Group 3 was fed with HCD and supplemented with 5 mg/kg/day of 172 
ezetimibe (positive control) while Group 4 was fed with HCD but not supplemented 173 
(negative control). Every group was constituted by 9-11 mice with at least 4 female mice 174 
per group. Mice blood was collected after 5 and 11 weeks. 175 
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The second experiment was carried out only with male mice. Three groups were 176 
made up: groups 3 and 4 were identical to the previous experiment and a new group 177 
(group 5) fed with HCD and supplemented with 400 mg/kg/day of hydrolysate. Every 178 
group was constituted by 5-6 mice. In this case, blood was collected after 4 and 8 weeks. 179 
 180 
2.7 Analyses of mice plasma 181 
Blood samples were collected using Z/Serum separator tubes (Aquisel, Barcelona, 182 
Spain) and let 15-30 min at room temperature until blood coagulation. After 183 
centrifugation at 1600g for 10 min, serum was collected and storage at -80 ºC until 184 
analysis. Serum levels (total cholesterol (TC), total triglycerides (TG), low-density 185 
lipoproteins (LDL-C), and high-density lipoproteins (HDL-C)) were determined using 186 
routine laboratory methods with a Cobas C311 Autoanalyzer (Roche, Basel, 187 
Switzerland). Two indices, atherogenic index (AI) and coronary risk index (CRI), were 188 










2.8 Identification of peptides by HPLC-MS/MS 193 
MS/MS detection was carried out with an electrospray quadrupole-time-of-flight 194 
(ESI-Q-TOF) series 6530 mass spectrometer coupled to a liquid chromatograph (model 195 
1100), both from Agilent Technologies (Pittsburgh, PA, USA). Analytical separation was 196 
carried out in an Ascentis Express Peptide ES-C18 column (100 mm x 2.1 mm, 2.7 μm 197 
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particle size) with a guard column (5 mm x 2.1 mm, 2.7 μm particle size), both from 198 
Supelco (Bellefonte, PA, USA). Mobile phases were: 0.3% (v/v) AA in water (phase A) 199 
and 0.3% (v/v) AA in ACN (phase B). Other chromatographic conditions were: injection 200 
volume, 15 μL; flow rate, 0.3 mL/min; column temperature, 25 ºC. The elution gradient 201 
was: 5% B for 10 min, 5–65% B in 35 min, 65-95% B in 2 min, and 95% B for 3 min. A 202 
reversed gradient from 95 to 5% B in 5 min was used to return to the initial eluting 203 
conditions.  204 
Mass spectrometer was operated in the full-scan mode from 100 to 1500 m/z and 205 
in the positive ion mode. ESI conditions were: fragmentator voltage, 200 V; nebulizer 206 
pressure, 50 psig; capillary voltage, 3500 V; gas temperature, 350 ºC; drying gas flow, 12 207 
L/min; and skimmer voltage, 60 V. The Jet Stream sheath gas temperature was 400 ºC 208 
and the flow was 12 L/min. MS/MS was carried out using Auto mode with the following 209 
conditions: 5 precursors per cycle and a collision energy of 4 V per each 100 Da. Two 210 
Agilent compounds (HP0921 and purine) yielding ions at 922.0098 m/z and 121.0509 211 
m/z, respectively, were simultaneously introduced and used as internal standards 212 
throughout the analysis.  213 
PEAKS Studio Version 7 software from Bioinformatics Solutions Inc. (Waterloo, 214 
Canada)15 was used for the analysis of MS/MS spectra and the novo sequencing of 215 
peptides. Two independent samples of the olive seed hydrolysate were injected by 216 
triplicate. Only peptides appearing in the three injections of the two independent samples 217 
with average local confidence (ALC, expected percentage of correct amino acids in the 218 
peptide sequence) equal or higher than 90 % were selected. Since it is not possible to 219 
differentiate between I and L amino acids due to their equal masses, only isoforms with 220 
L were presented, although peptide sequences containing I amino acid instead of L are 221 
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also possible. Isoelectric point and solubility in water were determined using Innovagen’s 222 
peptide property calculator.  223 
 224 
2.9 Statistical analysis 225 
Statistical analysis was performed using Statgraphics Software Plus 5.1 (Statpoint 226 
Technologies, Inc., Warranton, VA, USA). Data comparison was carried out by the 227 
analysis of variance (ANOVA) or the test-t. Duncan's Multiple Range test was used to 228 
determine statistically significant differences (p-value < 0.05). Results were expressed as 229 
mean ± standard deviation. 230 
  231 
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3. Results and discussion 232 
3.1 In vitro evaluation of hypocholesterolemic activity 233 
The capacity to reduce the bioavailability of dietary cholesterol and triglycerides 234 
of a hydrolysate obtained from olive seed proteins has been explored in a previous work 235 
observing a multifunctional effect.11 Indeed, results demonstrated that the olive seed 236 
hydrolysate showed capacity to reduce cholesterol micellar solubility and to inhibit the 237 
activity of cholesterol esterase and pancreatic lipase enzymes although it did not show 238 
capacity to bind bile acids. Biosynthesis of cholesterol is an additional source of 239 
cholesterol that contributes to hypercholesterolemia as much as exogenous cholesterol. 240 
Biosynthesis of cholesterol consists of different steps being the transformation of HMG-241 
CoA to mevalonate, the limiting one. This reaction is catalysed by the enzyme HMGR in 242 
presence of the cofactor NADPH. Therefore, HMGR is an important target against 243 
biosynthesis of cholesterol. In vitro HMGR inhibitory activity of the olive seed 244 
hydrolysate was determined at two different concentrations and results were compared 245 
with that of pravastatin, a drug usually employed for the treatment of 246 
hypercholesterolemia (see Figure 1). Olive seed hydrolysate reduced the activity of 247 
HMGR in 16.8 % when the peptide concentration was 3.1 mg/mL. This inhibition 248 
increased to a 40 % when the peptide concentration was 26.7 mg/mL. This activity is 249 
similar to the observed for hydrolysates obtained from amaranth16 and snakehead fish 250 
skin collagen.17 251 
 252 
  253 
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3.2 Cytotoxicity of the olive seed hydrolysate 254 
Safety of the olive seed hydrolysate was determined by the MTT assay using two 255 
different human cell lines, a cancer cell line (HeLa cells) and a healthy cell line (HK-2 256 
cells). Results shown in Figure 2 demonstrated cytotoxic effects in HeLa cells at 257 
concentrations higher than 3 mg/mL and a high cell viability in healthy HK-2 cells at any 258 
concentration.   259 
 260 
3.3 In vivo assay using a low olive seed hydrolysate concentration 261 
Olive seed hydrolysate has showed hypolipidemic activity in in vitro assays. 262 
Nevertheless, in vitro results do not always correlate with in vivo capacity since it depends 263 
on the bioavailability and temporal and spatial distribution of peptides in the body.18 264 
Therefore, a first in vivo assay was designed to evaluate the physiological effect of the 265 
olive seed hydrolysate. 266 
A preliminary assay was conducted using male and female mice in order to 267 
establish the effect of following a commercial hypercholesterolemic diet in serum lipids. 268 
The experiment took 11 weeks and serum TC was determined at week 4, 5, 8, and 11 269 
(Figure 3). Both male and female serum TC increased up to weeks 4-5 and, afterwards, it 270 
kept up to week 11.  271 
From these results, a new set of in vivo assays were designed to evaluate the effect 272 
of the administration of the olive seed hydrolysate. Four different groups were 273 
established: Group 1 was fed with a standard diet and daily treated with 200 mg/kg/day 274 
of the olive seed hydrolysate. This dose was selected based on previous studies found in 275 
bibliography that used doses ranging from 100 to 2500 mg/kg/day.19-22 Mice fed with 276 
normal diet and daily treated with the olive seed hydrolysate did not show any significant 277 
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variation in their serum lipids after 5 weeks (data not shown). Moreover, Group 2 was fed 278 
with HCD and daily treated with 200 mg/kg/day of the olive seed hydrolysate, Group 3 279 
was fed with HCD and daily treated with 5 mg/kg/day of hypocholesterolemic drug 280 
ezetimibe, and Group 4 was fed just with HCD. Table 1 shows lipid serum parameters 281 
obtained when using male mice. As expected from results in Figure 3, male mice fed with 282 
HCD showed a huge increase in TC level after 4 weeks but this level kept up to week 11. 283 
The administration of the olive seed hydrolysate reduced this serum TC in male mice in 284 
a 17% and a 20% after 5 and 11 weeks of administration, respectively. This result was 285 
compared with the obtained for Group 3 (supplemented with ezetimibe) observing that 286 
ezetimibe decreased the TC in a 11%, after 11 weeks.  287 
A similar experiment was conducted with female mice (see Table 2). The 288 
administration of 200 mg/kg/day of the olive seed hydrolysate for 11 weeks in female 289 
mice resulted in an increase in serum TC. Moreover, female mice neither showed a 290 
significant reduction in serum lipids when they were treated with ezetimibe for 11 weeks. 291 
The difference between male and female behaviour could be explained by the different 292 
hormonal cycles in the female organism.23 293 
In addition to TC, serum HDL-C and LDL-C were also determined (see Table 1 294 
and 2). HDL-C kept in serum male mice feeding with just HCD after 5 weeks and doubled 295 
when the olive seed hydrolysate was administrated for the same period. However, HDL-296 
C levels increased, in the same way, in the groups 2, 3, and 4 after 11 weeks. LDL-C in 297 
mice from group 4 increased more than LDL-C in mice from group 2, after 5 weeks. The 298 
same effect was appreciated in mice from groups 2 and 4, after 11 weeks. LDL-C levels 299 
in mice treated with ezetimibe did not show significant differences with mice from group 300 
2. Therefore, the hypocholesterolemic effect of the olive seed hydrolysate, observed after 301 
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5 and 11 weeks treatment, in male mice seems to be mainly due to the decrease in LDL-302 
C. This effect was similar in the ezetimibe group.  303 
Female mice showed an increase in HDL-C when they were treated with the olive 304 
seed hydrolysate while no significant variation in HDL-C was observed when they were 305 
treated with ezetimibe (see Table 2). This fact could explain the increase in TC observed 306 
for female mice treated with the hydrolysate. Female mice LDL-C kept after treatment 307 
with hydrolysate while it decreased when they were treated with ezetimibe. This result 308 
showed that, for female mice, the hypocholesterolemic effect of the hydrolysate was 309 
based on the increase of the HDL-C.  310 
Two different indexes, the atherogenic index (AI) and the coronary risk index 311 
(CRI), were calculated from lipid serum levels in male and female mice and results are 312 
shown in Table 1 and 2. Both, AI and CRI, are strong biomarkers to predict the risk of 313 
atherosclerosis and coronary heart diseases and they are more useful than independent 314 
serum parameters.24 Male mice feeding just with HCD resulted in a 215% and a 123% 315 
increase in AI and CRI, respectively, after 5 weeks treatment. After 11 weeks, these 316 
indexes showed a slight decrease due to the increase of HDL-C level, but they kept 317 
significantly higher than the rest of groups. Indeed, AI and CRI indexes in mice from 318 
groups supplemented with ezetimibe or hydrolysate were significantly lower than the 319 
indexes in the group fed only with HCD. The administration of the olive seed hydrolysate 320 
kept AI and CRI indexes in male mice during the whole experiment confirming the 321 
hypocholesterolemic effect, at physiological level, of the olive seed hydrolysate.  322 
Moreover, no significant variation in TG level was observed in male mice fed 323 
with HCD regardless they were treated with hydrolysate or ezetimibe. Similar results 324 
were observed for female mice except when they were treated with ezetimibe that resulted 325 
in a significant increase in TG level. 326 
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Taking into account the hypolipidemic effects observed in mice when they were 327 
treated with 200 mg/kg/day of the olive seed hydrolysate, a second in vivo assay with a 328 
higher dose was designed in order to find out whether it can produce a more significant 329 
effect. 330 
 331 
3.4 In vivo assay using a high olive seed hydrolysate concentration 332 
A new in vivo assay was carried out using a dose of 400 mg/kg/day of the olive 333 
seed hydrolysate and serum lipids were determined after 4 and 8 weeks of treatment. 334 
Figure 4 shows TC levels in the group fed with HCD and treated with ezetimibe (Group 335 
3), in the group fed with just HCD (Group 4), and in the group fed with HCD and treated 336 
with the new concentration of the olive seed hydrolysate (Group 5). As expected, TC 337 
increased in three groups after 4 weeks treatment not observing any significant difference 338 
in serum TC between them. However, after 8 weeks’ treatment, serum TC in mice treated 339 
with the olive seed hydrolysate (Group 5) decreased in a 25% while TC in mice within 340 
groups 4 and 3 kept at same levels than at week 4. This behaviour has also been observed 341 
in Figure 3 and in Table 1. The effect of ezetimibe treatment was observed after treatment 342 
for 11 weeks. The effect observed by the administration of 400 mg/kg/day of the olive 343 
seed hydrolysate at week 8 (25% reduction in TC) was more significant than the decrease 344 
in TC observed when using the dose of 200 mg/kg/day of the olive seed hydrolysate (20% 345 
reduction in TC at week 11). 346 
Like in the first assay, HDL-C, LDL-C, TG and two indexes were also determined 347 
at 8 weeks’ treatment (see Table 3). Serum HDL-C increased in the three groups after 8 348 
weeks. These increased was higher in mice supplemented with ezetimibe than in mice 349 
supplemented with hydrolysate. Furthermore, LDL-C levels decreased in a 44% and 26% 350 
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in groups 5 and 3, respectively, compared with negative control (group 4). Additionally, 351 
both indexes calculated, AI and CRI, were kept at initial values when mice were fed with 352 
HCD and supplemented with hydrolysate. The two indexes were significantly lower in 353 
mice supplemented with hydrolysate than in mice feeding just HCD. In the case of CRI, 354 
after 8 weeks, the index was even slightly lower than at the beginning of the treatment. 355 
The mice treated with ezetimibe showed the same AI value than those treated with 356 
hydrolysate. However, there was no significant difference in CRI indexes of groups 3 and 357 
4. Furthermore, Figure 5 shows the variation of mice weight during the assay in groups 4 358 
(HCD), 3 (HCD + ezetimibe), and 5 (HCD + hydrolysate). Animal weight increased in 359 
the same way in the three groups. At the end of the assay, all mice increased their body 360 
weight above 50%. This fact discards a secondary satiating effect of the olive seed 361 
hydrolysate. 362 
In vivo hypolipidemic effect of the olive seed hydrolysate was similar to the effect 363 
observed when purified peptides fractions were employed.25 Indeed, Rho et al.26 364 
demonstrated a reduction up to 25% in TC after treatment with a concentrated black 365 
soybean hydrolysate fraction for 4 weeks. Nagaoka et al.2 observed that the administration 366 
of a tryptic hydrolysate of the standard protein β-lactoglobulin produced a 17% reduction 367 
in TC in 48 h fasted rats. Moreover, Lapphanichayakool, Sutheerawattananonda, and 368 
Limpeanchob26 evaluated the hypocholesterolemic activity of sericin-derived peptides 369 
isolated from silk cocoons observing around a 28% TC reduction when a dose of 200 370 
mg/kg/day was administrated for 4 weeks. Another example was the work carried out by 371 
Zhong et al.19 that studied the in vivo hypocholesterolemic effect of a fraction from a 372 
soybean protein hydrolysate. They observed a 24% TC decrease when feeding mice with 373 
500 mg/kg/day and no effect when using 100 mg/kg/day doses.  374 
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In order to estimate the equivalence dose to obtain a similar effect in humans, it 375 
is necessary to consider that the metabolism of a high organism is slower than that of a 376 
mouse and it is necessary to apply a conversion factor. In the case of a mouse, the 377 
conversion factor from animal dose to human dose is 0.08128. Then, the human dose 378 
necessary to observe a similar effect, considering a 60 kg person, ranges from 0.97-1.9 g. 379 
 380 
3.5 Identification of peptides potentially responsible for the hypolipidemic effect of the 381 
olive seed hydrolysate 382 
In order to identify which peptides could be responsible for the observed 383 
hypolipidemic effect, the olive seed hydrolysate was analysed by RP-HPLC-MS/MS. 384 
Figure 6 shows the EIC (Extracted Ion Chromatogram) and the mass spectra of abundant 385 
peptides, FLPH and WNVN. Moreover, Table 4 shows the sequence of the identified 386 
peptides along with their molecular masses, retention time, mass accuracy, isoelectric 387 
point, and abundance (based on the areas obtained from extracted chromatograms). Only 388 
peptides appearing in the three injections of the two independent samples and with ALC 389 
equal or higher than 90 % were selected. Thirty-three different peptides with Mw lower 390 
than 1 kDa were identified. Identified peptides appeared in the first half of the TIC 391 
(between 1-24 min). Peptides had between 4-7 amino acids and showed isoelectric points 392 
ranging from 0 to 10. Almost half of peptides showed good solubility in water. Peptides 393 
contained a 56% of hydrophobic amino acids (alanine (A), leucine (L), phenylalanine (F), 394 
proline (P), methionine (M), valine (V), and tryptophan (W)), 10% of acidic amino acids 395 
(glutamic (E) and aspartic (D) acids) and 8% of basic amino acid lysine (K). Most 396 
abundant peptides were ADLY, FLPH, KLPLL, and TLVY. Two of these sequences, 397 
FDGEVK and VPLSPT, were previously observed, according to BIOPEP-UWM 398 
database, and showed antioxidant bioactivities while FAVV, KALM, KGAL, SSPL, and 399 
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TLVY are part of antibacterial peptides.29 Some peptides sequences were also observed 400 
in previous works of our research group11,30. Despite olive seed proteins are not sequenced 401 
in proteomic databases (there is no genomic data for the vast majority of olive proteins) 402 
yet, it has been possible the comparison of sequenced peptides with proteins identified in 403 
a previous work by homology with other plant species31. Indeed, two peptides, identified 404 
in this work, were within sequences of olive seed proteins: peptide ADIY (the sequence 405 
has been observed in protein Triticin OS=Triticum aestivum PE=2 SV=1 406 
(tr|B2CGM5|B2CGM5_WHEAT)) and peptide VYIE (the sequence has been observed 407 
in 11S globulin seed storage protein 2 OS=Sesamum indicum PE=2 SV=1 408 
(sp|Q9XHP0|11S2_SESIN))31.  Among identified peptides, it is interesting to highlight 409 
peptide FDGEVK since it has the same two C-terminal amino acids that a 410 
hypocholesterolemic peptide identified in the β-lactoglobulin tryptic hydrolysate.2 411 
In conclusion a hydrolysate obtained from olive seed proteins using Alcalase 412 
enzyme has demonstrated in vivo capacity to reduce serum cholesterol in mice at two 413 
different concentration levels (200 and 400 mg/kg/day). This effect was attributed to both, 414 
the increase of HDL-C and the decrease of LDL-C in serum. The treatment with the olive 415 
seed hydrolysate also kept initial atherogenic and coronary risk indexes. According to in 416 
vitro studies, this effect could be attributed to the capability showed by the olive seed 417 
hydrolysate to reduce the micellar cholesterol solubility and to inhibit important enzymes 418 
(pancreatic lipase, cholesterol esterase, and HMGR) involved in the biosynthesis and 419 
absorption of cholesterol. Analysis of mice weight also enabled to discard a possible 420 
satiating effect of the hydrolysate. Thirty-three different peptides were identified in the 421 
olive seed hydrolysate. All peptides showed a high content of hydrophobic amino acids 422 
being peptides ADLY, FLPH, KLPLL, and TLVY the most abundant. These peptides 423 




 This work was supported by the Spanish Ministry of Economy and 426 
Competitiveness (ref. AGL2016-79010-R) and the Comunidad Autónoma de Madrid and 427 





1. World Health Organization. Cardiovascular diseases (CVDs). Updated May 2017. 431 
Geneva, Switzerland: WHO. Available at: http://www.who.int/es/news-room/fact-432 
sheets/detail/cardiovascular-diseases-(cvds). 433 
2. Nagaoka, S.; Futamura, Y.; Miwa, K.; Awano, T.; Yamauchi, K.; Kanamaru, Y.; ... 434 
Kuwata, T. Identification of novel hypocholesterolemic peptides derived from bovine 435 
milk β-lactoglobulin. Biochem. Biophys. Res. Commun. 2001, 281, 11-17. 436 
3. Krause, B. R.; Sliskovic, D. R.; Anderson, M.; Homan, R. Lipid-lowering effects of 437 
WAY-121,898, an inhibitor of pancreatic cholesteryl ester hydrolase. Lipid. 1998, 33, 438 
489-498. 439 
4. Insull, J. W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: 440 
a scientific review. South. Med. J. 2006, 99, 257-273. 441 
5. Mattson, F. H.; Beck, L. W. The digestion in vitro of triglycerides by pancreatic 442 
lipase. J.  Biol. Chem. 1955, 214, 115-125. 443 
6. Goldstein, J. L.; Brown, M. S. Regulation of the mevalonate pathway. Nature. 444 
1990, 343, 425-430. 445 
7. Heidrich, J. E.; Contos, L. M.; Hunsaker, L. A.; Deck, L. M.; Vander Jagt, D. L. 446 
Inhibition of pancreatic cholesterol esterase reduces cholesterol absorption in the 447 
hamster. BMC pharmacol. 2004, 4, 670-673.  448 
8. Singh, R. B.; Niaz, M. A.; Ghosh, S. Hypolipidemic and antioxidant effects of 449 
Commiphora mukul as an adjunct to dietary therapy in patients with 450 
hypercholesterolemia. Cardiovasc. Drugs Ther. 1994, 8, 659-664. 451 
9. García, M.C.; Puchalska. P.; Esteve, C.; Marina, M.L. Vegetable foods: A cheap 452 
source of proteins and peptides with antihypertensive, antioxidant, and other less 453 
occurrence bioactivities. Talanta. 2013, 106, 328–349.  454 
22 
 
10. Lin, Y. H.; Tsai, J. S.; Chen, G. W. Purification and identification of 455 
hypocholesterolemic peptides from freshwater clam hydrolysate with in vitro 456 
gastrointestinal digestion. J. Food Biochem. 2017, 41, e12385. 457 
11. Prados, I. M.; Marina, M. L.; García, M. C. Isolation and identification by high 458 
resolution liquid chromatography tandem mass spectrometry of novel peptides with 459 
multifunctional lipid-lowering capacity. Food Res. Int. 2018, 111, 77-86. 460 
12. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram 461 
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 462 
1976, 72, 248-254.  463 
13. Marques, M. R.; Freitas, R. A. M. S.; Carlos, A. C. C.; Siguemoto, É. S.; Fontanari, 464 
G. G.; Arêas, J. A. G. Peptides from cowpea present antioxidant activity, inhibit 465 
cholesterol synthesis and its solubilisation into micelles. Food Chem. 2015, 168, 288-466 
293.  467 
14. Kai, N. S.; Nee, T. A.; Ling, E. L. C.; Ping, T. C.; Kamariah, L.; Lin, N. K. Anti–468 
hypercholesterolemic effect of kenaf (Hibiscus cannabinus L.) seed on high–fat diet 469 
Sprague dawley rats. Asian Pac. J. Tro. Med .2015, 8, 6-13. 470 
15. Ma, B.; Zhang, K.; Hendrie, C.; Liang, C.; Li, M.; Doherty‐Kirby, A.; Lajoie, G. 471 
PEAKS: powerful software for peptide de novo sequencing by tandem mass 472 
spectrometry. Rapid Commun. Mass Sp. 2003, 17, 2337-2342. 473 
16. Soares, R. A. M.; Mendonça, S.; de Castro, L. Í. A.; Menezes, A. C. C. C. C.; Arêas, 474 
J. A. G. Major peptides from amaranth (Amaranthus cruentus) protein inhibit HMG-475 
CoA reductase activity. Int. J. Mol. Sci. 2015, 16, 4150-4160. 476 
17. Virginia, A.; Rachmawati, H.; Riani, C.; Retnoningrum, D. S. Study of HMG-CoA 477 
Reductase Inhibition Activity of the Hydrolyzed Product of Snakehead Fish (Channa 478 
23 
 
striata) Skin Collagen with 50 kDa Collagenase from Bacillus licheniformis F11. 479 
4. Sci. Pharm. 2016, 84, 81-88. 480 
18. Motilva, M.J.; Serra, A.; Rubió, L. Nutrikinetic studies of food bioactive compounds: 481 
from in vitro to in vivo approaches, Int J. Food Sci. and Nutr. 2015, 66, S41-52. 482 
19. Zhong, F.; Liu, J.; Ma, J.; Shoemaker, C. F. Preparation of hypocholesterol peptides 483 
from soy protein and their hypocholesterolemic effects in mice. Food Res. Int. 2007, 484 
40, 661-667. 485 
20. Liu, C.; Lin, X. L.; Wan, Z.; Zou, Y.; Cheng, F. F.; Yang, X. Q. The physicochemical 486 
properties, in vitro binding capacities and in vivo hypocholesterolemic activity of 487 
soluble dietary fiber extracted from soy hulls. Food Funct. 2016, 7, 4830-4840. 488 
21. Cheurfa, M.; Allem, R. Study of hypocholesterolemic activity of Algerian Pistacia 489 
lenticus leaves extracts in vivo. Rev. Bras. Farmacogn. 2015, 25, 142-144.  490 
22. Khera, N.; Bhatia, A. Antihyperlipedemic activity of Woodfordis fructicos extract in 491 
high colesterol diet fed mice. Int. J. Pharm. Phytopharm. Res. 2012, 2, 211-215. 492 
23. Mumford, S. L.; Dasharathy, S.; Pollack, A. Z.; Schisterman, E. F. Variations in lipid 493 
levels according to menstrual cycle phase: clinical implications. Clin. lipidol. 2011, 494 
6, 225-234. 495 
24. Millán, J.; Pintó, X.; Muñoz, A.; Zúñiga, M.; Rubiés-Prat, J.; Pallardo, L. F.; Masana, 496 
L.; Mangas, A.; Hernández-Mijares, A.; González-Santos, P.; Ascaso, J. F.; … Pedro-497 
Botet, J. Lipoprotein ratios: Physiological significance and clinical usefulness in 498 
cardiovascular prevention. Vasc. Health Risk Manage. 2009, 5, 757-65. 499 
25. Howard, A.; Udenigwe, C. C. Mechanisms and prospects of food protein hydrolysates 500 
and peptide-induced hypolipidaemia. Food Funct. 2013, 4, 40-51. 501 
24 
 
26. Rho, S. J.; Park, S.; Ahn, C. W.; Shin, J. K.; Lee, H. G. Dietetic and 502 
hypocholesterolaemic action of black soy peptide in dietary obese rats. J. Sci. Food 503 
Agric. 2007, 87, 908-913. 504 
27. Lapphanichayakool, P.; Sutheerawattananonda, M.; Limpeanchob, N. 505 
Hypocholesterolemic effect of sericin-derived oligopeptides in high-cholesterol fed 506 
rats. J. Nat. Med. 2017, 71, 208-215. 507 
28. Nair, A. B.; Jacob, S. A simple practice guide for dose conversion between animals 508 
and human. Journal of basic and clinical pharmacy, 2016, 7, 27. 509 
29. Minkiewicz, P.; Iwaniak, A.; Darewicz, M. BIOPEP-UWM Database of Bioactive 510 
Peptides: Current Opportunities. Int. J Mol. Sci. 2019, 20, 5978. 511 
30. Esteve, C.; Marina, M. L.; García; M. C. Novel strategy for the revalorization of olive 512 
(Olea europaea) residues based on the extraction of bioactive peptides. Food Chem. 513 
2015, 167, 272-280. 514 
31. Esteve, C.; D'Amato, A.; Marina, M. L.; García, M. C.; Citterio, A.; Righetti, P. G. 515 
Identification of olive (Olea europaea) seed and pulp proteins by nLC-MS/MS via 516 




Figure captions 519 
Figure 1. Capacity of the olive seed hydrolysate to inhibit the enzyme HMGR at two 520 
different concentrations (3.1 and 26.7 mg/mL) in comparison with the positive control 521 
pravastatin. Means with different letters are significantly different (p < 0.05). 522 
Figure 2. Cell viability of human cell lines HK-2 and HeLa after treatment with the olive 523 
seed hydrolysate at different concentrations. Results are expressed as percentage related 524 
to the control value. Means with different letters are significantly different (p < 0.05). 525 
Figure 3. Variation of total cholesterol (TC) in serum male and female mice fed with 526 
HCD for 11 weeks. Values are expressed as mean ± standard deviation. Means with 527 
different letters are significantly different (p < 0.05). 528 
Figure 4. Variation of total cholesterol (TC) in serum male mice fed with HCD (Group 529 
3), with HCD and ezetimibe (Group 4), and with HCD and the olive seed hydrolysate 530 
(Group 5) after 4 and 8 weeks. Means with different letters are significantly different (p 531 
< 0.05). 532 
Figure 5. Variation of the body weight observed in male mice within Groups 3, 4, and 5 533 
during the assay that used 400 mg/kg/day. Means with different letters are significantly 534 
different (p < 0.05).  535 
Figure 6. Extracted Ion Chromatograms at 512 m/z (corresponding to peptide FLPH) and 536 
531 m/z (corresponding to peptide WNVN) and fragmentation spectra of these peptides. 537 
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Table 1.  Serum plasma levels in male mice fed with HCD (Group 4) and supplemented with 200 mg/kg/day of hydrolysate (Group 2) or ezetimibe 
(Group 3). Means with different letters are significantly different (p < 0.05). 
 
WEEK 0 WEEK 5 WEEK 11  
GROUP 4 GROUP 2  GROUP 4  GROUP 2  GROUP 3  
  (HCD) (HCD + Hydrolysate) (HCD) (HCD + Hydrolysate) (HCD + Ezetimibe) 
TC 138 ± 17a 274 ± 7c 227 ± 9b 263 ± 9c 209 ± 10b 234 ± 27b 
HDL-C 110 ± 6a' 97 ± 2a' 191 ± 10b' 188 ± 9b' 177 ± 7b' 185 ± 21b' 
LDL-C 22 ± 5a'' 61 ± 4cd'' 48 ± 2bc'' 66 ± 5d'' 48 ± 18bc'' 40 ± 11b'' 
TG 158 ± 36a''' 145 ± 14a''' 131 ± 26a''' 182 ± 35a''' 142 ± 45a''' 169 ± 31a''' 
AI 0.20 ± 0.03a'''' 0.63 ± 0.05c'''' 0.25 ± 0.00a'''' 0.35 ± 0.01b'''' 0.27 ± 0.09a'''' 0.23 ± 0.03a'''' 






Table 2.  Serum plasma levels in female mice fed with HCD (Group 4) and supplemented with 200 mg/kg/day of hydrolysate (Group 2) or 
ezetimibe (Group 3). Means with different letters are significantly different (p < 0.05). 
 
 WEEK 0 WEEK 11  
GROUP 4 GROUP 2 GROUP 3 
  (HCD) (HCD + Hydrolysate) (HCD + Ezetimibe) 
TC 93 ± 6a 122 ± 26b 160 ± 24c 118 ± 11ab 
HDL-C 75 ± 4a' 108 ± 24b' 137 ± 29c' 98 ± 9b' 
LDL-C 19 ± 3b'' 19 ± 4b'' 24 ± 7b'' 12 ± 4a'' 
TG 131 ± 35a''' 182 ± 53a'''b''' 164 ± 13a'''b''' 315 ± 42b''' 
AI 0.25 ± 0.03b'''' 0.18 ± 0.01a''''b'''' 0.17 ± 0.02a'''' 0.12 ± 0.04b'''' 




Serum plasma levels of male mice fed with HCD (Group 4) and supplemented with 400 mg/kg/day of hydrolysate (Group 5) or ezetimibe 
Means with different letters are significantly different (p < 0.05). 
WEEK 8 
GROUP 4 GROUP 5 GROUP 3 
(HCD) (HCD + Hydrolysate) (HCD + Ezetimibe) 
259 ± 61c 194 ± 31b 271 ± 23c 
271 ± 20c' 172 ± 36b' 213 ± 20c' 
62 ± 17c'' 35 ± 6b'' 46 ± 11b'' 
165 ± 36a''' 163 ± 75a''' 141 ± 27a''' 
0.31 ± 0.04b'''' 0.21 ± 0.02a'''' 0.24 ± 0.02a'''' 
1.28 ± 0.07b''''' 1.14 ± 0.04a''''' 1.28 ± 0.04b''''' 
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Table 4. Peptide sequence, average local confidence (ALC), retention time, molecular 
mass, mass accuracy (ppm), isoelectric point, water solubility, and abundance of peptides 
sequenced in the olive seed hydrolysate. 
PEPTIDE ALC 
(%) 






ADLY 92 9.63 480.222 -3.8 0.74 Good 115.3 ± 7.9 
AVFDD 95 13.73 565.2383 -5.1 0.73 Good 47.8 ± 4.4 
FAVV 94 21.32 434.2529 -5.2 0.00 Poor 9.8 ± 0.7 
FDGEVK 96 4.46 693.3333 -6.4 3.93 Good 75.1 ± 7.3 
FLPH 93 9.69 512.2747 -5.1 0.10 Poor 306.2 ± 8.9 
HTLY 92 5.02 532.2645 -5.4 0.10 Poor 36.5 ± 2.8 
KALM 96 3.24 461.2672 -4 9.91 Good 15.9 ± 0.9 
KFVEGDE 90 8.89 822.3759 -7.7 3.69 Good 7.3 ± 0.5 
KGAL 94 1.56 387.2481 -2.9 9.91 Good 20.5 ± 1.9 
KLGNF 93 16.03 577.3224 -7.6 9.91 Good 33.3 ± 0.8 
KLPL 97 18.9 469.3264 -5.9 9.91 Good 86.3 ± 4.0 
KLPLL 96 23.78 582.4105 -7 9.91 Poor 193.4 ± 10.8 
KVSSPL 93 12.37 629.3748 -7.7 9.91 Good 22.1 ± 2.7 
LAFK 93 9.13 477.2951 -7.8 10.12 Good 3.4 ± 1.3 
LLGL 94 23.36 414.2842 -7.5 3.63 Poor 4.2 ± 0.6 
LPVNTL 92 22.04 655.3904 -7.2 3.63 Poor 13.8 ± 2.1 
NDVFK 94 6.06 621.3122 -6 6.22 Good 14.7 ± 2.1 
NFVVLK 93 21.11 718.4377 -7.7 9.70 Poor 53.0 ± 7.5 
SSPL 92 5.18 402.2114 -3.2 3.37 Poor 15.1 ± 1.2 
SSPLL 96 20.18 515.2955 -6.1 3.37 Poor 20.4 ± 2.9 
STLF 94 21.42 466.2427 -6.6 3.43 Poor 28.2 ± 4.5 
SVLY 94 17.6 480.2584 -5.3 3.39 Poor 96.3 ± 8.6 
TLVY 95 17.97 494.274 -5.3 3.35 Poor 177.7 ± 15.1 
VDLE 96 7.51 474.2325 -3.9 0.71 Good 11.3 ± 0.7 
VFDGE 93 7.28 565.2383 -5.1 0.71 Good 20.1 ± 3.4 
VPLSPT 96 15.35 612.3483 -6.5 3.66 Poor 94.3 ± 7.1 
VVLK 99 2.55 457.3264 -2.5 10.10 Good 11.5 ± 0.5 
VVLLT 92 20.89 543.3632 -7 3.66 Poor 6.6 ± 0.4 
VVVPH 90 7.3 549.3275 -6.9 7.78 Poor 12.1 ± 1.2 
VYLE 92 15.37 522.2689 -4.2 1.00 Good 12.1 ± 1.9 
WDPN 91 5.92 530.2125 -3.2 0.78 Good 30.7 ± 3.4 
WNVN 91 13.91 531.2441 -6 3.59 Poor 75.5 ± 7.2 
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